NCT00845338View on ClinicalTrials.gov

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Multiple SclerosisOveractive Detrusor
Interventions
DRUG

Darifenacin (BAY79-4998)

Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days

Trial Locations (15)

10115

Berlin

20246

Hamburg

41063

Mönchengladbach

44627

Herne

45468

Mülheim

55131

Mainz

61440

Oberursel

69112

Heidelberg

72076

Tübingen

77933

Lahr

78054

Villingen-Schwenningen

79312

Emmendingen

82152

Planegg

99437

Bad Berka

06112

Halle

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY